{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:09:14Z","timestamp":1793423354141,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/501100007962","name":"Jikei University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ymgme.2017.12.428","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T08:46:45Z","timestamp":1513154805000},"page":"118-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II"],"prefix":"10.1016","volume":"123","author":[{"given":"Hiroo","family":"Hoshina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohta","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.12.428_bb0005","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","article-title":"The defect in the hunter syndrome: deficiency of sulfoiduronate sulfatase","volume":"70","author":"Bach","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymgme.2017.12.428_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0035","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00246-013-0653-0","article-title":"Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy","volume":"34","author":"Sato","year":"2013","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0040","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0050","doi-asserted-by":"crossref","first-page":"e102092","DOI":"10.1371\/journal.pone.0102092","article-title":"The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease","volume":"9","author":"Khanna","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.12.428_bb0055","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0065","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/humu.21516","article-title":"Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in beta-galactosidase deficiency","volume":"32","author":"Higaki","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0075","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/8904_2014_345","article-title":"Proteasome inhibitor bortezomib enhances the activity of multiple mutant forms of lysosomal alpha-glucosidase in Pompe disease","volume":"18","author":"Shimada","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","article-title":"Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II","volume":"107","author":"Higuchi","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ymgme.2015.05.009","article-title":"A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice","volume":"117","author":"Shimada","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jor.20507","article-title":"Effect of cell density on the rate of glycosaminoglycan accumulation by disc and cartilage cells in vitro","volume":"26","author":"Kobayashi","year":"2008","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0100","article-title":"Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G>A (p.Gln293Gln) synonymous variation in a female create exonic splicing","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.12.428_bb0105","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s004390050901","article-title":"Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients","volume":"103","author":"Karsten","year":"1998","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1005432600871","article-title":"Hunter disease in the Spanish population: molecular analysis in 31 families","volume":"21","author":"Gort","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0115","first-page":"21","article-title":"Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"36","author":"Li","year":"1999","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0120","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1021\/bi00083a012","article-title":"Specificity studies on the heparin lyases from Flavobacterium heparinum","volume":"32","author":"Desai","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymgme.2017.12.428_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0014-5793(87)81344-3","article-title":"Alginate-modifying enzymes: a proposed unified mechanism of action for the lyases and epimerases","volume":"212","author":"Gacesa","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0130","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00216-011-4671-6","article-title":"Inhibitor screening of pharmacological chaperones for lysosomal beta-glucocerebrosidase by capillary electrophoresis","volume":"399","author":"Shanmuganathan","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0135","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis","volume":"29","author":"Sukegawa-Hayasaka","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10038-005-0266-4","article-title":"Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II","volume":"50","author":"Kato","year":"2005","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.12.428_bb0145","doi-asserted-by":"crossref","first-page":"e0163964","DOI":"10.1371\/journal.pone.0163964","article-title":"Structural basis of mucopolysaccharidosis type II and construction of a database of mutant iduronate 2-sulfatases","volume":"11","author":"Saito","year":"2016","journal-title":"PLoS One"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T08:38:00Z","timestamp":1535186280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217306583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1096719217306583"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.428","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}